Appointments and Second Opinions

Speak with one of our New Patient Coordinators to schedule an appointment, refer a patient or request a second opinion. In urgent cases, we can typically see new patients within 24 hours.

Contact us
Find Clinical Trials

We sponsor and collaborate on clinical trials that break new ground in pediatric cancer and blood disorder treatment. 

Search Pediatric Cancer and Blood Disorder Clinical Trials
Our Affiliations
HMS Affiliate

Dana-Farber/Boston Children's is a teaching affiliate of Harvard Medical School.

Our Affiliations

Scott A. Armstrong, MD, PhD

  • President, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
  • Chairman, Department of Pediatric Oncology
  • Associate Chief, Division of Hematology/Oncology, Boston Children's Hospital
  • David G. Nathan Professor of Pediatrics, Harvard Medical School
  • Chief Research Strategy Officer
  • Senior Vice President for Drug Discovery

Appointment Phone

  • 888-733-4662 (New Pediatric Patients)
  • 617-632-3270 (Established Pediatric Patients)

Fax

  • 617-632-4367

General

Treatment Centers

Discipline

Clinical Interests

Hematologic malignancies

Location

Background

Board Certifications

  • Pediatric Hematology/Oncology, 2002

Fellowship

  • Boston Children's Hospital/Dana-Farber Cancer Institute, Pediatric Hematology/Oncology, 2001

Residency

  • Boston Combined Residency Program, Boston Children's Hospital/Boston Medical Center, Pediatrics, 1998

Internships

  • Boston Combined Residency Program, Boston Children's Hospital/Boston Medical Center, Pediatrics, 1998

Medical School

  • University of Texas Southwestern Medical School, 1996

Biography

Scott A. Armstrong, MD PhD, was appointed Senior Vise President for Drug Discovery and Chief Research Strategy Officer in 2024, leading Dana-Farber's institutional research strategy focusing on our therapeutic discovery efforts.  Dr. Armstrong became the President of Dana-Farber/Boston Children's Cancer and Blood Disorders Center in 20219 and has been Chairman of the Department of Pediatric Oncology at Dana-Farber Cancer Institute since 2016.  He is also the David G. Nathan Professor of Pediatrics at Harvard Medical School and associate chief of the Division of Hematology/Oncology at Boston Children's Hospital.

Dr. Armstrong was previously director of the Center for Epigenetics Research at Memorial Sloan Kettering Cancer Center and Professor of Pediatrics at the Weil Cornell Medical College.  He earned his medical degree and PhD from University of Texas Southwestern Medical School in 1996.  After internship and residency training with the Boston Combined Residency Program (BCRP) at Boston Medical Center and Boston Children's Hospital, he completed a hematology/oncology fellowship at Dana-Farber/Boston Children's Cancer and Blood Disorders Center.

The major focus of Dr. Armstrong's career has been on delineating the biology of childhood cancers and the development of new therapeutic approaches for children with cancer.  His research program has focused on the mechanisms of leukemia development and the relationship between leukemia and normal hematopoietic stem cells.  Dr. Armstrong continues to direct a vigorous research program that focuses on development of the new therapeutics that target chromatin-based mechanisms, and he is actively involved in the development and translation of a number of new small molecule approaches that likely will be tested in clinical trials in the near future.